All lobbying filings

THE KPM GROUP DC LLC

THE KPM GROUP DC LLC filed a Q3 report for SOLENO THERAPEUTICS, INC. on October 13, 2025, reporting $50,000 in lobbying income.

Lobbying for SOLENO THERAPEUTICS, INC. · Soleno is focused on development of novel therapeutics for treatment of rare diseases.

All filings by THE KPM GROUP DC LLC · Everything SOLENO THERAPEUTICS, INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 13, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

H.R.946, Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R.1262/S.932, Give Kids a Chance Act H.R.1414, Camerons Law H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.1492/S.832, EPIC Act S.527, Prescription Pricing for the People Act H.R.2450, Prescription Drug Transparency and Affordability Act S.882, Patients Before Middlemen Act S.526, Pharmacy Benefit Manager Transparency Act

Bills named in this filing 12

H.R. 946
ORPHAN Cures Act
H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025
H.R. 1414
Cameron’s Law
H.R. 1509
Accelerating Kids’ Access to Care Act of 2025
S. 752
Accelerating Kids’ Access to Care Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S. 832
EPIC Act of 2025
S. 527
Prescription Pricing for the People Act of 2025
H.R. 2450
Prescription Drug Transparency and Affordability Act
S. 882
Patients Before Middlemen Act
S. 526
Pharmacy Benefit Manager Transparency Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.